Cargando…

Systematic Assessment of Fragment Identification for Multitarget Drug Design

Designed multitarget ligands are a popular approach to generating efficient and safe drugs, and fragment‐based strategies have been postulated as a versatile avenue to discover multitarget ligand leads. To systematically probe the potential of fragment‐based multiple ligand discovery, we have employ...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunst, Steffen, Kramer, Jan S., Kilu, Whitney, Heering, Jan, Pollinger, Julius, Hiesinger, Kerstin, George, Sven, Steinhilber, Dieter, Merk, Daniel, Proschak, Ewgenij
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049054/
https://www.ncbi.nlm.nih.gov/pubmed/33283450
http://dx.doi.org/10.1002/cmdc.202000858
_version_ 1783679355692515328
author Brunst, Steffen
Kramer, Jan S.
Kilu, Whitney
Heering, Jan
Pollinger, Julius
Hiesinger, Kerstin
George, Sven
Steinhilber, Dieter
Merk, Daniel
Proschak, Ewgenij
author_facet Brunst, Steffen
Kramer, Jan S.
Kilu, Whitney
Heering, Jan
Pollinger, Julius
Hiesinger, Kerstin
George, Sven
Steinhilber, Dieter
Merk, Daniel
Proschak, Ewgenij
author_sort Brunst, Steffen
collection PubMed
description Designed multitarget ligands are a popular approach to generating efficient and safe drugs, and fragment‐based strategies have been postulated as a versatile avenue to discover multitarget ligand leads. To systematically probe the potential of fragment‐based multiple ligand discovery, we have employed a large fragment library for comprehensive screening on five targets chosen from proteins for which multitarget ligands have been successfully developed previously (soluble epoxide hydrolase, leukotriene A4 hydrolase, 5‐lipoxygenase, retinoid X receptor, farnesoid X receptor). Differential scanning fluorimetry served as primary screening method before fragments hitting at least two targets were validated in orthogonal assays. Thereby, we obtained valuable fragment leads with dual‐target engagement for six out of ten target combinations. Our results demonstrate the applicability of fragment‐based approaches to identify starting points for polypharmacological compound development with certain limitations.
format Online
Article
Text
id pubmed-8049054
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80490542021-04-20 Systematic Assessment of Fragment Identification for Multitarget Drug Design Brunst, Steffen Kramer, Jan S. Kilu, Whitney Heering, Jan Pollinger, Julius Hiesinger, Kerstin George, Sven Steinhilber, Dieter Merk, Daniel Proschak, Ewgenij ChemMedChem Communications Designed multitarget ligands are a popular approach to generating efficient and safe drugs, and fragment‐based strategies have been postulated as a versatile avenue to discover multitarget ligand leads. To systematically probe the potential of fragment‐based multiple ligand discovery, we have employed a large fragment library for comprehensive screening on five targets chosen from proteins for which multitarget ligands have been successfully developed previously (soluble epoxide hydrolase, leukotriene A4 hydrolase, 5‐lipoxygenase, retinoid X receptor, farnesoid X receptor). Differential scanning fluorimetry served as primary screening method before fragments hitting at least two targets were validated in orthogonal assays. Thereby, we obtained valuable fragment leads with dual‐target engagement for six out of ten target combinations. Our results demonstrate the applicability of fragment‐based approaches to identify starting points for polypharmacological compound development with certain limitations. John Wiley and Sons Inc. 2021-02-04 2021-04-08 /pmc/articles/PMC8049054/ /pubmed/33283450 http://dx.doi.org/10.1002/cmdc.202000858 Text en © 2020 The Authors. ChemMedChem published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Communications
Brunst, Steffen
Kramer, Jan S.
Kilu, Whitney
Heering, Jan
Pollinger, Julius
Hiesinger, Kerstin
George, Sven
Steinhilber, Dieter
Merk, Daniel
Proschak, Ewgenij
Systematic Assessment of Fragment Identification for Multitarget Drug Design
title Systematic Assessment of Fragment Identification for Multitarget Drug Design
title_full Systematic Assessment of Fragment Identification for Multitarget Drug Design
title_fullStr Systematic Assessment of Fragment Identification for Multitarget Drug Design
title_full_unstemmed Systematic Assessment of Fragment Identification for Multitarget Drug Design
title_short Systematic Assessment of Fragment Identification for Multitarget Drug Design
title_sort systematic assessment of fragment identification for multitarget drug design
topic Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049054/
https://www.ncbi.nlm.nih.gov/pubmed/33283450
http://dx.doi.org/10.1002/cmdc.202000858
work_keys_str_mv AT brunststeffen systematicassessmentoffragmentidentificationformultitargetdrugdesign
AT kramerjans systematicassessmentoffragmentidentificationformultitargetdrugdesign
AT kiluwhitney systematicassessmentoffragmentidentificationformultitargetdrugdesign
AT heeringjan systematicassessmentoffragmentidentificationformultitargetdrugdesign
AT pollingerjulius systematicassessmentoffragmentidentificationformultitargetdrugdesign
AT hiesingerkerstin systematicassessmentoffragmentidentificationformultitargetdrugdesign
AT georgesven systematicassessmentoffragmentidentificationformultitargetdrugdesign
AT steinhilberdieter systematicassessmentoffragmentidentificationformultitargetdrugdesign
AT merkdaniel systematicassessmentoffragmentidentificationformultitargetdrugdesign
AT proschakewgenij systematicassessmentoffragmentidentificationformultitargetdrugdesign